To specifically inhibit p110α, p110β, p110δ, and p110γ we employed A-66, TGX-221, CAL-101, and AS-605240, respectively, whose selectivity has been reported elsewhere [14, 15, 25], and that, at least in several instances, have shown effectiveness in hematological malignancies [26]. Here, PIK3CD is linked to hematologic disorder.